特应性皮炎的全程管理共识

doi:10.35541/cjd.20220618

Abstract

Abstract: 【Abstract】 Atopic dermatitis （AD） is a common pruritic, chronic, inflammatory dermatosis. The prevalence of AD has increased rapidly during the past 20 years, and it places the heaviest disease burden among non-fatal skin diseases. Therefore, it is urgent to carry out effective whole-process management of atopic dermatitis in clinical practice. This consensus is a set of AD management plans following previous guidelines and clinical consensus, based on the characteristics of AD in terms of prevention, treatment, rehabilitation, care, etc., aiming to provide a scientific and authoritative reference for the whole-process management of AD in China.

Key words: Dermatitis, atopic, Whole-process management, Consensus

Immunology Group, Chinese Society of Dermatology. Consensus on the whole-process management of atopic dermatitis[J]. Chinese Journal of Dermatology, 2023, 56(1): 5-15.doi:10.35541/cjd.20220618

References ［57］

［1］	中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南（2020版）［J］. 中华皮肤科杂志, 2020,53（2）:81⁃88. doi: 10.35541/cjd.20191000.
［2］	Dong WL, An J, Yu M, et al. The prevalence and year lived with disability of atopic dermatitis in China: findings from the global burden of disease study 2019［J］. World Allergy Organ J, 2021,14（11）:100604. doi: 10.1016/j.waojou.2021.100604.
［3］	Thyssen JP, Corn G, Wohlfahrt J, et al. Retrospective markers of paediatric atopic dermatitis persistence after hospital diagnosis: a nationwide cohort study［J］. Clin Exp Allergy, 2019,49（11）:1455⁃1463. doi: 10.1111/cea.13487.
［4］	Laughter MR, Maymone M, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990⁃2017［J］. Br J Dermatol, 2021,184（2）:304⁃309. doi: 10.1111/bjd.19580.
［5］	Tsai TF, Rajagopalan M, Chu CY, et al. Burden of atopic dermatitis in Asia［J］. J Dermatol, 2019,46（10）:825⁃834. doi: 10.1111/1346⁃8138.15048.
［6］	Girolomoni G, de Bruin⁃Weller M, Aoki V, et al. Nomenclature and clinical phenotypes of atopic dermatitis［J］. Ther Adv Chronic Dis, 2021,12:204062232 11002979. doi: 10.1177/204062 23211002979.
［7］	Lyons JJ, Milner JD, Stone KD. Atopic dermatitis in children: clinical features, pathophysiology, and treatment［J］. Immunol Allergy Clin North Am, 2015,35（1）:161⁃183. doi: 10.1016/j.iac. 2014.09.008.
［8］	李巍. 特应性皮炎与过敏进程［J］. 医学与哲学, 2014,35（6）:12⁃14.
［9］	张洪明, 叶巍岭, 郭焱, 等. 监护人对儿童特应性皮炎认知情况的调查［J］. 中国麻风皮肤病杂志, 2013,29（9）:572⁃574. doi: 10.3969/j.issn.1009⁃1157.2013.09.010.
［10］	田晶, 申春平, 马琳. 患者治疗教育在儿童特应性皮炎长期治疗管理中的作用［J］. 中国皮肤性病学杂志, 2016,30（7）:691⁃694. doi: 10.13735/j.cjdv.1001⁃7089.201511102.
［11］	Capozza K, Schwartz A. Does it work and is it safe? Parents′ perspectives on adherence to medication for atopic dermatitis［J］. Pediatr Dermatol, 2020,37（1）:58⁃61. doi: 10.1111/pde. 13991.
［12］	Wollenberg A, Christen⁃Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children［J］. J Eur Acad Dermatol Venereol, 2020,34（12）:2717⁃2744. doi: 10. 1111/jdv.16892.
［13］	高莹, 邓维. 儿童特应性皮炎的诊断及鉴别诊断［J］. 中国医刊, 2020,55（10）:1061⁃1064. doi: 10.3969/j.issn.1008⁃1070. 2020.10.005.
［14］	姚煦. 常用特应性皮炎严重度评估方法［J］. 中华皮肤科杂志, 2021,54（6）:539⁃541. doi: 10.35541/cjd.20200825.
［15］	宋志强, 王欢. 特应性皮炎的治疗进展: 新药物、新手段、新模式［J］. 中华皮肤科杂志, 2021,54（2）:161⁃164. doi: 10.35541/cjd.20201028.
［16］	梁云生, 余艺昕, 杨斌. 系统抗炎是重度免疫性皮肤病达标治疗的关键［J］. 中华医学杂志, 2021,101（16）:1119⁃1122. doi: 10.3760/cma.j.cn112137⁃20201209⁃03313.
［17］	顾于蓓, 李玥. 炎症性肠病达标治疗面临的优势与困境［J］. 中华炎性肠病杂志, 2018,（2）:124⁃126. doi: 10.3760/cma.j.issn.2096⁃367X.2018.02.012.
［18］	Smith S, Baker C, Gebauer K, et al. Atopic dermatitis in adults: an Australian management consensus［J］. Australas J Dermatol, 2020,61（1）:23⁃32. doi: 10.1111/ajd.13124.
［19］	Megna M, Napolitano M, Patruno C, et al. Systemic treatment of adult atopic dermatitis: a review［J］. Dermatol Ther （Heidelb）, 2017,7（1）:1⁃23. doi: 10.1007/s13555⁃016⁃0170⁃1.
［20］	De Bruin⁃Weller M, Biedermann T, Bissonnette R, et al. Treat⁃to⁃target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies［J］. Acta Derm Venereol, 2021,101（2）:adv00402. doi: 10.2340/00015555⁃3751.
［21］	赵作涛, 高兴华. 中重度特应性皮炎系统药物达标治疗专家指导建议［J］. 中国皮肤性病学杂志, 2022,36（08）:855⁃864. doi:10.13735/j.cjdv.1001⁃7089.202205115.
［22］	Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis⁃⁃an emerging concept［J］. Allergy, 2009,64（2）:276⁃278. doi: 10. 1111/j.1398⁃9995.2008.01803.x.
［23］	中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组, 中华医学会皮肤性病学分会儿童学组, 中国老年保健医学研究会皮肤科分会. 特应性皮炎外用制剂合理应用及患者指导专家共识［J］. 中华皮肤科杂志, 2022,55（4）:281⁃288. doi: 10.35541/cjd.20210833.
［24］	Augustin M, Langenbruch A, Blome C, et al. Characterizing treatment⁃related patient needs in atopic eczema: insights for personalized goal orientation［J］. J Eur Acad Dermatol Venereol, 2020,34（1）:142⁃152. doi: 10.1111/jdv.15919.
［25］	王珊, 何黎, 王华, 等. 功效性护肤品在儿童特应性皮炎中的应用指南［J］. 中国皮肤性病学杂志, 2020,34（9）:977⁃981. doi: 10.13735/j.cjdv.1001⁃7089.202006019.
［26］	中华医学会皮肤性病学分会儿童皮肤病学组. 中国儿童特应性皮炎诊疗共识（2017版）［J］. 中华皮肤科杂志, 2017,50（11）:784⁃789. doi: 10.3760/cma.j.issn.0412⁃4030.2017.11.002.
［27］	中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组, 中华医学会皮肤性病学分会儿童学组. 特应性皮炎湿包疗法临床应用专家共识［J］. 中华皮肤科杂志, 2022,55（4）:289⁃294. doi: 10.35541/cjd.20210823.
［28］	Wollenberg A, Barbarot S, Bieber T, et al. Consensus⁃based European guidelines for treatment of atopic eczema （atopic dermatitis） in adults and children: part II［J］. J Eur Acad Dermatol Venereol, 2018,32（6）:850⁃878. doi: 10.1111/jdv. 14888.
［29］	Davari DR, Nieman EL, McShane DB, et al. Current perspectives on the systemic management of atopic dermatitis［J］. J Asthma Allergy, 2021,14:595⁃607. doi: 10.2147/JAA.S287638.
［30］	Wollenberg A, Ehmann LM. Long term treatment concepts and proactive therapy for atopic eczema［J］. Ann Dermatol, 2012,24（3）:253⁃260. doi: 10.5021/ad.2012.24.3.253.
［31］	Pariser D. Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption［J］. Am J Ther, 2009,16（3）:264⁃273. doi: 10.1097/MJT.0b013e31818a975c.
［32］	Chittock J, Brown K, Cork MJ, et al. Comparing the effect of a twice⁃weekly tacrolimus and betamethasone valerate dose on the subclinical epidermal barrier defect in atopic dermatitis［J］. Acta Derm Venereol, 2015,95（6）:653⁃658. doi: 10.2340/00015 555⁃2048.
［33］	Wollenberg A, Reitamo S, Atzori F, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment［J］. Allergy, 2008,63（6）:742⁃750. doi: 10.1111/j.1398⁃9995.2008. 01683.x.
［34］	Thaçi D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study［J］. Br J Dermatol, 2008,159（6）:1348⁃1356. doi: 10.1111/j.1365⁃2133.2008.08813.x.
［35］	Berth⁃Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study［J］. BMJ, 2003,326（7403）:1367. doi: 10.1136/bmj.326.7403.1367.
［36］	Peserico A, Städtler G, Sebastian M, et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double⁃blind, controlled study［J］. Br J Dermatol, 2008,158（4）:801⁃807. doi: 10.1111/j.1365⁃2133.2008.08436.x.
［37］	Merola JF, Sidbury R, Wollenberg A, et al. Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52⁃week randomized controlled phase 3 trial［J］. J Am Acad Dermatol, 2021,84（2）:495⁃497. doi: 10.1016/j.jaad.2020.05.003.
［38］	Ferreira S, Torres T. Dupilumab para el tratamiento de la dermatitis atópica［J］. Actas Dermo⁃Sifiliográficas, 2018,109（3）:230⁃240. doi: 10.1016/j.ad.2017.10.012.
［39］	Beck LA, Deleuran M, Bissonnette R, et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open⁃label study of adults with moderate⁃to⁃severe atopic dermatitis［J］. Am J Clin Dermatol, 2022,23（3）:393⁃408. doi: 10.1007/s40257⁃022⁃00685⁃0.
［40］	田晶, 马琳. 特应性皮炎患者教育［J］. 中国医学文摘（皮肤科学）, 2016,33（02）:201⁃205.
［41］	LeBovidge JS, Elverson W, Timmons KG, et al. Multidisciplinary interventions in the management of atopic dermatitis［J］. J Allergy Clin Immunol, 2016,138（2）:325⁃334. doi: 10.1016/j.jaci.2016.04.003.
［42］	van Os⁃Medendorp H, Koffijberg H, Eland⁃de Kok PC, et al. E⁃health in caring for patients with atopic dermatitis: a randomized controlled cost⁃effectiveness study of internet⁃guided monitoring and online self⁃management training［J］. Br J Dermatol, 2012,166（5）:1060⁃1068. doi: 10.1111/j.1365⁃2133.2012.10829.x.
［43］	Winslow A, Keet CA. Preventing allergies through the skin［J］. Ann Allergy Asthma Immunol, 2022,129（3）:276⁃285. doi: 10. 1016/j.anai.2022.04.013.
［44］	Lowe AJ, Leung D, Tang M, et al. The skin as a target for prevention of the atopic march［J］. Ann Allergy Asthma Immunol, 2018,120（2）:145⁃151. doi: 10.1016/j.anai.2017.11.023.
［45］	Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention［J］. J Allergy Clin Immunol, 2014,134（4）:818⁃823. doi: 10.1016/j.jaci.2014.08.005.
［46］	Horimukai K, Morita K, Narita M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis［J］. J Allergy Clin Immunol, 2014,134（4）:824⁃830.e6. doi: 10. 1016/j.jaci.2014.07.060.
［47］	Chalmers JR, Haines RH, Bradshaw LE, et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial［J］. Lancet, 2020,395（10228）:962⁃972. doi: 10. 1016/S0140⁃6736（19）32984⁃8.
［48］	Sindher S, Alkotob SS, Shojinaga MN, et al. Pilot study measuring transepidermal water loss （TEWL） in children suggests trilipid cream is more effective than a paraffin⁃based emollient［J］. Allergy, 2020,75（10）:2662⁃2664. doi: 10.1111/all.14275.
［49］	Skjerven HO, Lie A, Vettukattil R, et al. Early food intervention and skin emollients to prevent food allergy in young children （PreventADALL）: a factorial, multicentre, cluster⁃randomised trial［J］. Lancet, 2022,399（10344）:2398⁃2411. doi: 10.1016/S0140⁃6736（22）00687⁃0.
［50］	Allen KJ, Koplin JJ, Ponsonby AL, et al. Vitamin D insufficiency is associated with challenge⁃proven food allergy in infants［J］. J Allergy Clin Immunol, 2013,131（4）:1109⁃1116, 1116.e1⁃6. doi: 10.1016/j.jaci.2013.01.017.
［51］	Hennessy Á, Hourihane JO, Malvisi L, et al. Antenatal vitamin D exposure and childhood eczema, food allergy, asthma and allergic rhinitis at 2 and 5 years of age in the atopic disease⁃specific Cork BASELINE Birth Cohort Study［J］. Allergy, 2018,73（11）:2182⁃2191. doi: 10.1111/all.13590.
［52］	Tsiaras WG, Weinstock MA. Factors influencing vitamin D status［J］. Acta Derm Venereol, 2011,91（2）:115⁃124. doi: 10.2340/00015555⁃0980.
［53］	Kim G, Bae JH. Vitamin D and atopic dermatitis: a systematic review and meta⁃analysis［J］. Nutrition, 2016,32（9）:913⁃920. doi: 10.1016/j.nut.2016.01.023.
［54］	Korpela K, Helve O, Kolho KL, et al. Maternal fecal microbiota transplantation in cesarean⁃born infants rapidly restores normal gut microbial development: a proof⁃of⁃concept study［J］. Cell, 2020,183（2）:324⁃334.e5. doi: 10.1016/j.cell.2020.08.047.
［55］	Wilson BC, Butler ÉM, Grigg CP, et al. Oral administration of maternal vaginal microbes at birth to restore gut microbiome development in infants born by caesarean section: a pilot randomised placebo⁃controlled trial［J］. EBioMedicine, 2021,69:103443. doi: 10.1016/j.ebiom.2021.103443.
［56］	Cuello⁃Garcia CA, Brożek JL, Fiocchi A, et al. Probiotics for the prevention of allergy: a systematic review and meta⁃analysis of randomized controlled trials［J］. J Allergy Clin Immunol, 2015,136（4）:952⁃961. doi: 10.1016/j.jaci.2015.04.031.
［57］	Garcia⁃Larsen V, Ierodiakonou D, Jarrold K, et al. Diet during pregnancy and infancy and risk of allergic or autoimmune disease: a systematic review and meta⁃analysis［J］. PLoS Med, 2018,15（2）:e1002507. doi: 10.1371/journal.pmed.1002507.

[1]	Acne Study Group of China Dermatologist Association, Dermatology Professional Committee of Chinese Research Hospital Association, Acne Study Group of Dermatology and Venereology Professional Committee of Chinese Association of Integrative Medicine. Chinese expert consensus on clinical severity grading and therapeutic evaluation of acne vulgaris （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(8): 709-714.
[2]	Chinese Society of Dermatology, China Dermatologist Association. Expert consensus on the diagnosis and treatment of localized scleroderma （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(8): 699-708.
[3]	Hair Research Group, Chinese Society of Dermatology. Chinese expert consensus on the diagnosis and treatment of lichen planopilaris/frontal fibrosing alopecia （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(7): 583-590.
[4]	Chinese Society of Dermatology, China Dermatologist Association. Recommendations for the diagnosis and treatment pathway for hereditary angioedema:a dermatology expert group consensus （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(6): 497-502.
[5]	The Consensus Development Expert Group on Diagnosis and Treatment of Port-wine Stain in Chinese Children, Pediatric Dermatologist Committee, China Dermatologist Association. Expert consensus on diagnosis and treatment of port-wine stain in children （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 396-404.
[6]	China Dermatologist Association, Treatment Group, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, National Clinical Research Center for Dermatologic and Immunologic Diseases, Rare Skin Diseases Committee, China Alliance for Rare Diseases. Diagnosis and treatment of bullous pemphigoid: an expert consensus statement （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 405-415.
[7]	Skin Cancer Research Group, Committee on Dermatology, Chinese Association of Integrative Medicine, Melanoma Society of China Anti-Cancer Association, Society of Integrated Rehabilitation of Skin Tumors, China Anti-Cancer Association. Expert consensus on diagnosis and treatment of pigmented nevi （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 387-395.
[8]	Group on Children, Chinese Society of Dermatology, Dermatology and Venereology Group, Chinese Pediatric Society, Chinese Medical Association, Chinese Association of Rehabilitation Dermatology, Pediatric Dermatology Group, China Dermatologist Association. Expert consensus on the construction of specialized outpatient clinics and standardized case management of children with atopic dermatitis in China （2025 version） [J]. Chinese Journal of Dermatology, 2025, 0(4): 20240338-e20240338.
[9]	Group on Pediatric Dermatology, China Dermatologist Association, Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on the diagnosis and treatment of pediatric pustular psoriasis in China （2025 version） [J]. Chinese Journal of Dermatology, 2025, 58(4): 297-306.
[10]	Chinese Society of Dermatology, China Dermatologist Association, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, Rare Skin Diseases Committee, China Alliance for Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases. Expert consensus on the diagnosis and treatment of paraneoplastic pemphigus in China （2025 version） [J]. Chinese Journal of Dermatology, 2025, 58(4): 289-296.
[11]	Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment, Patient Education Expert Committee, Chinese Society of Clinical Oncology . Chinese expert consensus on multidisciplinary management of cancer treatment related cutaneous adverse events [J]. Chinese Journal of Dermatology, 2025, 0(4): 20250344-e20250344.
[12]	Chinese Association of Rehabilitation Dermatology, Chinese Society of Dermatology, Photomedicine Therapeutic Equipment Group, Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment. Clinical application of red, blue, and yellow light therapy in dermatology: an expert consensus statement （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(3): 209-215.
[13]	Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment. Expert consensus on the treatment of dermatoses with targeted drugs （2025 version） [J]. Chinese Journal of Dermatology, 2025, 58(2): 99-125.
[14]	Chinese Society of Dermatology, China Dermatologist Association. Expert consensus on diagnosis and treatment of pyoderma gangrenosum （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(12): 1121-1129.
[15]	The Expert Panel for the “Expert Consensus on the Topical Treatment and Management of Atopic Dermatitis（ edition）”. Expert consensus on the topical treatment and management of atopic dermatitis （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(10): 903-909.

Consensus on the whole-process management of atopic dermatitis

PDF

Knowledge

Abstract

Cite this article

share this article

References ［57］

Related Articles 15

Metrics

Comments

Recommended 10